The rupture of membranes tests market is projected to grow from USD 935.7 million in 2026 to USD 1,892.9 million by 2036, at a CAGR of 7.3%. Immunoassay-based tests will dominate with a 56.0% market share, while preterm prom will lead the application segment with a 66.0% share.